MARKET

VKTX

VKTX

Viking Therapeutics Inc
NASDAQ
27.58
-0.86
-3.02%
After Hours: 27.63 +0.05 +0.18% 19:52 11/12 EST
OPEN
27.91
PREV CLOSE
28.44
HIGH
28.56
LOW
27.49
VOLUME
2.19M
TURNOVER
--
52 WEEK HIGH
43.15
52 WEEK LOW
23.82
MARKET CAP
3.52B
P/E (TTM)
-5.1020
1D
5D
1M
3M
1Y
5Y
1D
Corbus Pharmaceuticals Holdings Inc. Stock Sheds 14.8%, Underperforms Peers
Dow Jones · 7h ago
Viking Therapeutics (VKTX) Stock Could Be Pricey Following VK2735 Obesity Data Plans
Simply Wall St · 18h ago
Eli Lilly Just Raised Its 2026 Sales Forecast to as Much as $92 Billion. But Is Viking Therapeutics the Next Big Obesity Winner?
The Motley Fool · 1d ago
Obesity Trial Data Might Change The Case For Investing In Viking Therapeutics Stock
Simply Wall St · 1d ago
Corbus Pharmaceuticals Holdings Inc. Stock Advances 11.6%, Outperforms Peers
Dow Jones · 2d ago
Corbus Pharmaceuticals Holdings Inc. Stock Rises 14.7%, Outperforms Peers
Dow Jones · 3d ago
Viking Therapeutics (VKTX) Moved, What Is Drawing Attention Now?
Simply Wall St · 3d ago
Viking Therapeutics Announces Two Poster Presentations at ObesityWeek® 2026
PR Newswire · 3d ago
More
About VKTX
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company that is focused on the development of therapies for the treatment of metabolic and endocrine disorders. Its clinical programs include VK2735, a novel dual agonist of the glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide receptors for the potential treatment of various metabolic disorders. It is evaluating an oral formulation of VK2735 in a Phase II trial. It is also developing VK2809, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders. Its newest program is evaluating a series of internally developed dual amylin and calcitonin receptor agonists for the treatment of obesity and other metabolic disorders. In the rare disease space, it is developing VK0214, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the potential treatment of X-linked adrenoleukodystrophy.

Webull offers Viking Therapeutics Inc stock information, including NASDAQ: VKTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VKTX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading VKTX stock methods without spending real money on the virtual paper trading platform.